APO866 induces cell death in various hematologic malignant cell lines
| Disease diagnosis/Cell line name . | 96 hours APO866 . | |
|---|---|---|
| EC50 MTT, nM . | FDC, 10 nM, % . | |
| Acute myeloid leukemia | ||
| ML-2 (AML-M4) | 0.13 ± 0.03 | 99 |
| THP-1 (AML-M5) | 0.30 ± 0.05 | 99 |
| NOMO-1 (AML-M5) | 0.09 ± 0.02 | 98 |
| NB4 (AML-M3) | 2.88 ± 0.58 | 93 |
| MV4–11 (AML-M5) | 0.33 ± 0.12 | 92 |
| MOLM-13 (AML-M5) | 1.69 ± 0.35 | 92 |
| Mutz-2 (AML-M2) | 5.80 ± 0.51 | 89 |
| HEL (AML-M6) | 1.20 ± 0.16 | 74 |
| SKM-1 (AML-M5) | N/A | 73 |
| OCI-M1 (AML-M6) | N/A | 72 |
| Kasumi-1 (AML-M2) | 2.27 ± 0.15 | 68 |
| HL-60 (AML-M2) | 3.62 ± 1.33 | 67 |
| UT-7 (AML-M7) | 22.72 ± 5.15 | 47 |
| Acute lymphoblastic leukemia | ||
| Molt-4 | 1.14 ± 0.14 | 87 |
| Jurkat | 0.24 ± 0.06 | 80 |
| CCRF-CEM | 0.39 ± 0.10 | 23 |
| B-chronic lymphocytic leukemia | ||
| Mec-2 | 8.43 ± 2.89 | 73 |
| EHEB | 5.68 ± 0.65 | 65 |
| Mec-1 | 4.32 ± 0.74 | 55 |
| CML | ||
| k562 | 7.20 ± 0.92 | 36 |
| Burkitt lymphoma | ||
| Bjab | 1.34 ± 0.16 | 89 |
| Ramos | 10.64 ± 1.06 | 89 |
| Namalwa | 6.33 ± 4.45 | 87 |
| Daudi | 13.21 ± 5.26 | 36 |
| Raji | 2.22 ± 0.12 | 30 |
| Follicular lymphoma | ||
| DOHH-2 | 0.86 ± 0.03 | 89 |
| SC-1 | 2.03 ± 0.48 | 85 |
| Hodgkin lymphoma | ||
| L428 | 14.64 ± 2.12 | 57 |
| Histiocytic lymphoma | ||
| U937 | 8.35 ± 0.49 | 83 |
| Cutaneous T-cell lymphoma | ||
| Myla | 1.20 ± 0.18 | 97 |
| Hut78 | 2.83 ± 0.37 | 82 |
| Multiple myeloma | ||
| OPM-2 | 3.11 ± 0.17 | 97 |
| MOLP-8 | N/A | 90 |
| RPMI8226 | 8.98 ± 0.20 | 77 |
| IM9 | 27.22 ± 5.4 | 77 |
| ARH-77 | 12.19 ± 1.58 | 65 |
| KMS-12-BM | N/A | 63 |
| EJM | N/A | 63 |
| L-363 | 15.6 ± 1.97 | 33 |
| U266 | 26.9 ± 5.3 | 26 |
| EBV-transformed B-lymphocyte | ||
| SKW6.4 | 8.17 ± 0.7 | 81 |
| Disease diagnosis/Cell line name . | 96 hours APO866 . | |
|---|---|---|
| EC50 MTT, nM . | FDC, 10 nM, % . | |
| Acute myeloid leukemia | ||
| ML-2 (AML-M4) | 0.13 ± 0.03 | 99 |
| THP-1 (AML-M5) | 0.30 ± 0.05 | 99 |
| NOMO-1 (AML-M5) | 0.09 ± 0.02 | 98 |
| NB4 (AML-M3) | 2.88 ± 0.58 | 93 |
| MV4–11 (AML-M5) | 0.33 ± 0.12 | 92 |
| MOLM-13 (AML-M5) | 1.69 ± 0.35 | 92 |
| Mutz-2 (AML-M2) | 5.80 ± 0.51 | 89 |
| HEL (AML-M6) | 1.20 ± 0.16 | 74 |
| SKM-1 (AML-M5) | N/A | 73 |
| OCI-M1 (AML-M6) | N/A | 72 |
| Kasumi-1 (AML-M2) | 2.27 ± 0.15 | 68 |
| HL-60 (AML-M2) | 3.62 ± 1.33 | 67 |
| UT-7 (AML-M7) | 22.72 ± 5.15 | 47 |
| Acute lymphoblastic leukemia | ||
| Molt-4 | 1.14 ± 0.14 | 87 |
| Jurkat | 0.24 ± 0.06 | 80 |
| CCRF-CEM | 0.39 ± 0.10 | 23 |
| B-chronic lymphocytic leukemia | ||
| Mec-2 | 8.43 ± 2.89 | 73 |
| EHEB | 5.68 ± 0.65 | 65 |
| Mec-1 | 4.32 ± 0.74 | 55 |
| CML | ||
| k562 | 7.20 ± 0.92 | 36 |
| Burkitt lymphoma | ||
| Bjab | 1.34 ± 0.16 | 89 |
| Ramos | 10.64 ± 1.06 | 89 |
| Namalwa | 6.33 ± 4.45 | 87 |
| Daudi | 13.21 ± 5.26 | 36 |
| Raji | 2.22 ± 0.12 | 30 |
| Follicular lymphoma | ||
| DOHH-2 | 0.86 ± 0.03 | 89 |
| SC-1 | 2.03 ± 0.48 | 85 |
| Hodgkin lymphoma | ||
| L428 | 14.64 ± 2.12 | 57 |
| Histiocytic lymphoma | ||
| U937 | 8.35 ± 0.49 | 83 |
| Cutaneous T-cell lymphoma | ||
| Myla | 1.20 ± 0.18 | 97 |
| Hut78 | 2.83 ± 0.37 | 82 |
| Multiple myeloma | ||
| OPM-2 | 3.11 ± 0.17 | 97 |
| MOLP-8 | N/A | 90 |
| RPMI8226 | 8.98 ± 0.20 | 77 |
| IM9 | 27.22 ± 5.4 | 77 |
| ARH-77 | 12.19 ± 1.58 | 65 |
| KMS-12-BM | N/A | 63 |
| EJM | N/A | 63 |
| L-363 | 15.6 ± 1.97 | 33 |
| U266 | 26.9 ± 5.3 | 26 |
| EBV-transformed B-lymphocyte | ||
| SKW6.4 | 8.17 ± 0.7 | 81 |
FDC indicates fraction of dead cells at 10 nM APO866, corresponding to percentage of annexin V–stained positive cells; and N/A, not analyzed